Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1362-1369

  Pollack, Ian F ^a   Erff, Melanie ^a   Ashkenazi, Avi ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLASPARTYLGLUTAMYLVALYLASPARTIC ACID ALDEHYDE; ACETYLTYROSYLVALYLALANYLASPARTYLCHLOROMETHYLKETONE; CASPASE INHIBITOR; CELL SURFACE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CELL KILLING; CONTROLLED STUDY; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR STEM CELL ASSAY;

EID: 0034906370     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Apoptosis. Its significance in cancer and cancer therapy
2. p53 status and the efficacy of cancer therapy in vivo
3. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome
4. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
5. p53-dependent, and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α
6. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood
7. Clonal expansion of p53 mutant cells is associated with brain tumor progression
8. Co-expression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance
9. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines
10. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas
11. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo
12. Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors
13. Expression of two types of receptor for insulin-like growth factors in human malignant glioma
14. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification
15. Prognostic factors in the management of pediatric malignant gliomas
16. Death receptors: Signaling and modulation
17. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
18. Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells
19. Apoptosis by death factor
20. Lethal effect of the anti-Fas antibody in mice
21. Identification and characterization of a new member of the TNF family that induces apoptosis
22. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
23. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
24. The receptor for the cytotoxic ligand TRAIL
25. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
26. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
27. Characterization of two receptors for TRAIL
28. KILLER/DR5 is a DNA damage-inducible p53-regulated cell death receptor gene
29. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
30. A novel receptor for Apo2L/TRAIL contains a truncated death domain
31. The novel receptor TRAIL-R4 induces NF-ΚB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
32. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling
33. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
34. Apo2 ligand: A novel lethal weapon against malignant glioma?
35. Safety and antitumor activity of recombinant soluble Apo2 ligand
36. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis
37. Experimental therapy of human glioma by means of a genetically engineered virus mutant
38. Caspases: Enemies within
39. Programmed cell death in animal development
40. Mechanisms and genes of cellular suicide
41. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
42. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo